Crestline Management’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History

Crestline Management’s Portfolio FSTX Stock Details FSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-4,055	Closed	-$249K	–	299
2018 Q1	$249K	Sell	4,055 -4,156	-51%	-$219K	0.03%	207
2017 Q4	$442K	Sell	8,211 -7,529	-48%	-$448K	0.05%	144
2017 Q3	$1.06M	Sell	15,740 -8,905	-36%	-$510K	0.15%	96
2017 Q2	$1.33M	Buy	+24,645	New	+$1.14M	0.18%	66

Other funds holding FSTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Tiedemann Advisors New York $2.33B AUM 15.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

PCM

Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return

MAM

Morse Asset Management Darien, Connecticut $481M AUM 46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Crestline Management's FSTX Position: Q2 2018 in Review

Crestline Management sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q2 2018, closing a stake of 4,055 shares — an estimated $249K sold.

Crestline Management first reported a position in FSTX in Q2 2017 and held it in 4 quarters. The position peaked at $1.33M in Q2 2017. 52 funds tracked by Wall St. Rank hold FSTX as of Q2 2018.

Crestline Management reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
Crestline Management sold 4,055 F-star Therapeutics, Inc. Common Stock shares in Q2 2018, an estimated $249K.
Crestline Management first reported a position in F-star Therapeutics, Inc. Common Stock in Q2 2017 and held it in 4 quarters.
Crestline Management's F-star Therapeutics, Inc. Common Stock position peaked at $1.33M in Q2 2017.
52 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q2 2018.

Based on Crestline Management's 13F filing for Q2 2018, filed 14 Aug 2018.